Healthcare authorities are increasingly looking at budgets and requesting proven efficacy and cost-effectiveness evidence to support drug submissions; this presents a challenge for getting orphan drugs (ODs) approved.
The rate of OD approvals appears to be falling, and ODs are more likely to gain approval in the USA than in the EU. 2 One reason behind this trend could be the requirement of robust clinical data for cost-effectiveness calculations. These data are challenging to obtain when a very small population is affected by a disease. As such, cost-effectiveness data are often not included or are limited in OD HTA submissions. 3 Furthermore, the impact of an OD is often only significant for the individual, not the whole population, making HTAs naturally biased against ODs because the objective of the HTA is to maximise public health.
This research explores the current and alternative approaches to assessing the economic value of ODs within the existing HTA framework.
• Assessing the economic value of ODs within the existing HTA framework is a challenge mainly because of low patient numbers for clinical trials, lack of long-term data, lack of important outcomes and limitations in accepted statistical methods
• Alternative approaches have been discussed in published literature, but none of these approaches have been used in recent HTA submissions
• HTA bodies, companies developing ODs, patients and society on both national and international levels must engage in further discussions on how to assess the value of ODs
• Access to ODs will continue to be unequal compared to non-ODs and across countries until approaches such as those described here are followed Challenges for assessing the economic value of orphan drugs -a literature review of current and alternative approaches A structured literature search was completed in July 2014. There were two stages of searching:
1) A targeted search of published literature that discusses alternative approaches for assessing the economic value of ODs 2) A targeted search of recent HTA submissions for ODs across six key EU markets (France, Germany, Ireland, the Netherlands, Sweden and the UK)
Literature search
The search was kept broad in the initial electronic searches as the literature/evidence base for ODs can be very small. Due to the varied nature of the papers of interest, we focused the screening efforts for the manual review of titles, abstracts and full papers. A search protocol was produced, detailing inclusion and exclusion criteria as well as search methods.
The following databases where searched for this element of the review:
• MEDLINE and MEDLINE In-Process (using PubMed)
• Cochrane Library (NHS Economic Evaluation Database and HTA database)
• Web of Science (to identify conference abstracts/materials)
The population of interest was orphan or ultra-orphan diseases. The literature search focused on orphan diseases in general, not on specific diseases. Studies focusing on pharmacological interventions for orphan diseases were included; any studies focusing on the assessment of non-pharmacological interventions were excluded. Identified studies discussed methods designed to assess the economic value of ODs.
All study types were considered, and papers were not restricted by language. Literature searches were limited to studies published after 1 January 2000, which were expected to have more methodological relevance. Figure 1 shows the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) diagram.
PSY126 Current challenges for ODs
The literature review identified several challenges for evaluating ODs within the existing HTA framework, which are listed here:
• Insufficient evidence of efficacy [4] [5] [6] [7] • High uncertainty around clinical outcomes (especially when analysed using frequentist clinical trial statistics) 7, 8 • Inability to identify subgroups or responders/non-responders 7, 8 • Insufficient evidence for other important outcomes, e.g. quality of life and patient reported outcomes 5, 8 • Lack of long-term outcomes data 5, 8 • Lack of information on the wider systemic impact of the disease 5, 8 • High drug cost 4 Most of the issues are due to the low patient numbers available for clinical trials for ODs. This leads to inadequate evidence for HTAs and difficulties in quantifying the true benefit of ODs in terms of clinical outcomes and quality of life. These factors increase the uncertainty of both the clinical efficacy and the cost effectiveness of the product, which, combined with high prices for ODs, lead to incremental cost-effectiveness ratios far beyond normal thresholds.
Inconsistent HTA decisions
The HTA review showed no difference in the clinical data or the approach taken by the manufacturer in the HTA submissions across countries. Despite this consistency, only one product (pomalidomide) achieved the same outcome (positive) across all countries where it was submitted (France, Germany and Sweden -all have less emphasis on the economic evaluation). This shows a lack of consistency in the decisions taken by HTA bodies leading to unequal access to ODs across countries.
Alternative approaches
We identified several alternative approaches in the literature to overcome the challenges for HTA evaluation of ODs, which we have summarised below:
• Societal value, variable thresholds and weighted outcome measures There is a difference in values defined in cost-effectiveness thresholds and values defined by society when it comes to the evaluation of ODs. 7, 9 This warrants a debate to define the value of ODs. 8 Thresholds should be variable and determined by societal values, e.g. setting a higher threshold for ODs, or equity weights should be determined for outcomes in orphan diseases, increasing the health gain in evaluations of ODs 10
• Cost and burden of illness studies The cost and burden of illness for an orphan disease should be established before an economic evaluation, ideally including a standardised approach for economic evaluation at the disease level. This should focus on what are the appropriate outcomes to assess and the particular features of the disease. 6 Such disease-specific 'reference cases' already exist for other disease areas, but have only recently been developed for some orphan diseases through the BURQOL-RD project 11 • Additional data collection and innovative early access schemes More registries should be established and observational studies carried out in orphan diseases. Despite the absence of a control group, these studies provide valuable information on the best standard of care, use of other treatments, adherence and natural history of the disease. 6, 7 Launching a compulsory EU orphan disease registry following marketing authorisation of an OD is one approach already being discussed. 8, 12 Innovative schemes linking data collection to early access to ODs should be established, e.g. conditional reimbursement or coverage with evidence development 8 • Biomarkers, surrogate endpoints and innovative statistical approaches Criteria to validate biomarkers and surrogate endpoints should be developed for orphan diseases, similar to those already established in other disease areas (e.g. rheumatology). 6 Within the same framework, the use of alternative statistical approaches (e.g. multivariate regression) should also be explored to establish the link between biomarkers, surrogate endpoints and the real outcomes of interest 6 
